APA (7th ed.) Citation

F, J., OA, J., SL, P., PA, K., F, M., JA, Z., . . . KT, F. (2025). PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. JCO precision oncology, 9, e2500265. https://doi.org/10.1200/PO-25-00265

Chicago Style (17th ed.) Citation

F, Janku, et al. "PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P." JCO Precision Oncology 9 (2025): e2500265. https://doi.org/10.1200/PO-25-00265.

MLA (9th ed.) Citation

F, Janku, et al. "PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P." JCO Precision Oncology, vol. 9, 2025, p. e2500265, https://doi.org/10.1200/PO-25-00265.